Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2026)

Royalty Pharma has disclosed Other Non Operating Income across 8 years of filings, most recently posting -$2.2 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$2.2 million, up 28.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.5 million (down 1390.5% YoY), and the FY2025 annual result was -$14.3 million, down 839.07% from the prior year.
• Other Non Operating Income came in at -$2.2 million for Q1 2026 at Royalty Pharma, up from -$8.2 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $6.0 million in Q2 2024 to a low of -$18.3 million in Q4 2023.
• The 5-year median for Other Non Operating Income is -$1.8 million (2022), against an average of -$3.2 million.
• Across the five-year window, Other Non Operating Income tumbled 4186.05% in 2022 and soared 449.95% in 2024, its largest moves.
• Royalty Pharma's Other Non Operating Income stood at -$1.2 million in 2022, then tumbled by 1471.5% to -$18.3 million in 2023, then soared by 88.04% to -$2.2 million in 2024, then slumped by 273.23% to -$8.2 million in 2025, then jumped by 73.06% to -$2.2 million in 2026.
• The last three Other Non Operating Income figures came in at -$2.2 million (Q1 2026), -$8.2 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.